mesalamine has been researched along with 2019 Novel Coronavirus Disease in 14 studies
Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our understanding of coronavirus disease 2019 (COVID-19) and its implications for patients with inflammatory bowel diseases (IBD) is rapidly evolving." | 2.82 | COVID-19 and Outcomes in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. ( Godoy Brewer, G; Limketkai, BN; Parian, AM; Saleh Ismail, M; Sauk, JS; Singh, Y; Thu Nguyen, M; Tripathi, K, 2022) |
| "Ulcerative colitis was diagnosed 6 months earlier and treated with mesalamine 80 mg/kg/day and azathioprine 2." | 1.72 | SARS-CoV-2 (COVID-19) pneumonia patient treated with two doses of infliximab within 2 weeks for acute severe ulcerative colitis: A case report. ( Abbas, A; Alhalabi, M; Ali, F; Eddin, KA, 2022) |
| "The majority of patients had Crohn's disease (CD) (60%) and most of them were in clinical remission." | 1.62 | COVID-19 in IBD: The experience of a single tertiary IBD center. ( Belluzzi, A; Calabrese, C; Calandrini, L; Decorato, A; Dussias, N; Filippone, E; Gionchetti, P; Laureti, S; Melotti, L; Peruzzi, G; Poggioli, G; Privitera, H; Rizzello, F; Rottoli, M; Salice, M; Scaioli, E; Siniscalchi, A, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 14 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ungaro, RC | 2 |
| Brenner, EJ | 2 |
| Agrawal, M | 1 |
| Zhang, X | 2 |
| Kappelman, MD | 2 |
| Colombel, JF | 2 |
| Tripathi, K | 1 |
| Godoy Brewer, G | 1 |
| Thu Nguyen, M | 1 |
| Singh, Y | 1 |
| Saleh Ismail, M | 1 |
| Sauk, JS | 1 |
| Parian, AM | 1 |
| Limketkai, BN | 1 |
| Kjeldsen, S | 1 |
| Nielsen, J | 1 |
| Mertz Nørgård, B | 1 |
| Kjeldsen, J | 1 |
| Alvarado, DM | 1 |
| Son, J | 1 |
| Thackray, LB | 1 |
| Gomez Castro, MF | 1 |
| Prasad, S | 1 |
| Cui, X | 1 |
| Sonnek, NM | 1 |
| Diamond, MS | 1 |
| Ding, S | 1 |
| Ciorba, MA | 1 |
| Alhalabi, M | 1 |
| Eddin, KA | 1 |
| Ali, F | 1 |
| Abbas, A | 1 |
| Aparicio Serrano, A | 1 |
| Gallego Jiménez, E | 1 |
| Castro Rodríguez, J | 1 |
| Soto Escribano, P | 1 |
| Iglesias Flores, E | 1 |
| Marín Pedrosa, S | 1 |
| Benítez, JM | 1 |
| Choi, SY | 1 |
| Choi, S | 1 |
| Kang, B | 1 |
| Choe, BH | 1 |
| Lee, YJ | 1 |
| Park, JH | 1 |
| Kim, YB | 1 |
| Kim, JY | 3 |
| Lee, K | 1 |
| Lee, KJ | 1 |
| Kang, KS | 1 |
| Lee, YM | 1 |
| Kim, HJ | 1 |
| Kang, Y | 1 |
| Jang, HJ | 1 |
| Yi, DY | 1 |
| Hong, SJ | 1 |
| Choi, YJ | 1 |
| Hong, J | 1 |
| Kim, SC | 1 |
| Lee, MH | 2 |
| Li, HJ | 2 |
| Wasuwanich, P | 2 |
| Kim, SE | 2 |
| Jeong, GH | 2 |
| Park, S | 2 |
| Yang, JW | 2 |
| Kim, MS | 2 |
| Yon, DK | 2 |
| Lee, SW | 2 |
| Koyanagi, A | 2 |
| Jacob, L | 2 |
| Kim, EY | 2 |
| Cheon, JH | 2 |
| Shin, JI | 2 |
| Smith, L | 2 |
| Mouhtar El Hálabi, S | 1 |
| Valdés Delgado, T | 1 |
| Maldonado Pérez, B | 1 |
| Belvis Jiménez, M | 1 |
| Argüelles Arias, F | 1 |
| Mazza, S | 1 |
| Sorce, A | 1 |
| Peyvandi, F | 1 |
| Vecchi, M | 1 |
| Caprioli, F | 1 |
| Pigneur, B | 1 |
| Focht, G | 1 |
| Turner, D | 1 |
| Ruemmele, FM | 1 |
| Rizzello, F | 1 |
| Calabrese, C | 1 |
| Salice, M | 1 |
| Calandrini, L | 1 |
| Privitera, H | 1 |
| Melotti, L | 1 |
| Peruzzi, G | 1 |
| Dussias, N | 1 |
| Belluzzi, A | 1 |
| Scaioli, E | 1 |
| Decorato, A | 1 |
| Siniscalchi, A | 1 |
| Filippone, E | 1 |
| Laureti, S | 1 |
| Rottoli, M | 1 |
| Poggioli, G | 1 |
| Gionchetti, P | 1 |
| Attauabi, M | 1 |
| Seidelin, J | 1 |
| Burisch, J | 1 |
| Roy, S | 1 |
| Sheikh, SZ | 1 |
| Furey, TS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Monitoring Serologic Response to SARS-COV-2 / Coronavirus Disease 2019 (COVID-19) in Children, Adolescents, and Young Adults Receiving Biologic Therapies (RECONN)[NCT04838834] | 472 participants (Actual) | Observational | 2020-05-15 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for mesalamine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
COVID-19 and Outcomes in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.
Topics: Adrenal Cortex Hormones; COVID-19; Humans; Inflammatory Bowel Diseases; Mesalamine; Necrosis; Tumor | 2022 |
COVID-19 susceptibility and clinical outcomes in inflammatory bowel disease: An updated systematic review and meta-analysis.
Topics: Adrenal Cortex Hormones; Colitis, Ulcerative; COVID-19; Crohn Disease; Humans; Inflammatory Bowel Di | 2023 |
COVID-19 susceptibility and clinical outcomes in inflammatory bowel disease: An updated systematic review and meta-analysis.
Topics: Adrenal Cortex Hormones; Colitis, Ulcerative; COVID-19; Crohn Disease; Humans; Inflammatory Bowel Di | 2023 |
COVID-19 susceptibility and clinical outcomes in inflammatory bowel disease: An updated systematic review and meta-analysis.
Topics: Adrenal Cortex Hormones; Colitis, Ulcerative; COVID-19; Crohn Disease; Humans; Inflammatory Bowel Di | 2023 |
COVID-19 susceptibility and clinical outcomes in inflammatory bowel disease: An updated systematic review and meta-analysis.
Topics: Adrenal Cortex Hormones; Colitis, Ulcerative; COVID-19; Crohn Disease; Humans; Inflammatory Bowel Di | 2023 |
12 other studies available for mesalamine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry.
Topics: Adrenal Cortex Hormones; COVID-19; Humans; Inflammatory Bowel Diseases; Mesalamine; Registries; SARS | 2022 |
Mesalazine in Inflammatory Bowel Disease and COVID-19: Hospitalization and Adverse In-Hospital Outcomes Based on Nationwide Data.
Topics: Colitis, Ulcerative; COVID-19; Crohn Disease; Hospitalization; Hospitals; Humans; Inflammatory Bowel | 2022 |
Mesalamine Reduces Intestinal ACE2 Expression Without Modifying SARS-CoV-2 Infection or Disease Severity in Mice.
Topics: Angiotensin-Converting Enzyme 2; Animals; COVID-19; Intestines; Mesalamine; Mice; SARS-CoV-2; Severi | 2022 |
SARS-CoV-2 (COVID-19) pneumonia patient treated with two doses of infliximab within 2 weeks for acute severe ulcerative colitis: A case report.
Topics: Adult; Azathioprine; Colitis, Ulcerative; COVID-19; COVID-19 Drug Treatment; Humans; Infliximab; Mal | 2022 |
Mesalazine induced interstitial pneumonitis in the COVID era.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; COVID-19; Humans; Lung Diseases, Inter | 2022 |
Epidemiological Trends of Pediatric Inflammatory Bowel Disease in Korea: A Multicenter Study of the Last 3 Years Including the COVID-19 Era.
Topics: Azathioprine; Colitis, Ulcerative; COVID-19; Crohn Disease; Humans; Inflammatory Bowel Diseases; Inf | 2022 |
Severe outbreak of ulcerative colitis and cerebral neoplasia. Difficult management in COVID time.
Topics: Colitis, Ulcerative; COVID-19; Disease Outbreaks; Humans; Male; Mesalamine; Middle Aged; Neoplasms | 2023 |
A fatal case of COVID-19 pneumonia occurring in a patient with severe acute ulcerative colitis.
Topics: Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Betacoronavirus; Clini | 2020 |
Benign Evolution of SARS-Cov2 Infections in Children With Inflammatory Bowel Disease: Results From Two International Databases.
Topics: Adolescent; Ambulatory Care; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Co | 2021 |
COVID-19 in IBD: The experience of a single tertiary IBD center.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Biological Products; | 2021 |
Association between 5-aminosalicylates in patients with IBD and risk of severe COVID-19: an artefactual result of research methodology?
Topics: Colitis, Ulcerative; COVID-19; Humans; Mesalamine; Research Design; SARS-CoV-2 | 2021 |
A machine learning approach identifies 5-ASA and ulcerative colitis as being linked with higher COVID-19 mortality in patients with IBD.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, P | 2021 |